About Annexon, Inc.
https://www.annexonbio.comAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
CEO
Douglas E. Love
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FMR LLC
Shares:11.08M
Value:$74.02M
BLACKROCK, INC.
Shares:7.9M
Value:$52.77M
ALERCE INVESTMENT MANAGEMENT, L.P.
Shares:7.41M
Value:$49.47M
Summary
Showing Top 3 of 157
About Annexon, Inc.
https://www.annexonbio.comAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $57.02M ▲ | $-54.92M ▼ | 0% | $-0.37 ▼ | $-54.38M ▼ |
| Q2-2025 | $0 | $51.73M ▼ | $-49.16M ▲ | 0% | $-0.34 ▲ | $-51.11M ▲ |
| Q1-2025 | $0 | $57.41M ▲ | $-54.36M ▼ | 0% | $-0.37 ▼ | $-56.87M ▼ |
| Q4-2024 | $0 | $52.48M ▲ | $-48.59M ▼ | 0% | $-0.33 ▼ | $-51.94M ▼ |
| Q3-2024 | $0 | $39.44M | $-34.82M | 0% | $-0.25 | $-38.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $188.72M ▼ | $229.14M ▼ | $67.7M ▲ | $161.44M ▼ |
| Q2-2025 | $227.02M ▼ | $264.57M ▼ | $65.56M ▲ | $199.02M ▼ |
| Q1-2025 | $263.7M ▼ | $303.03M ▼ | $59.24M ▲ | $243.79M ▼ |
| Q4-2024 | $312.02M ▼ | $350.07M ▼ | $56.97M ▲ | $293.11M ▼ |
| Q3-2024 | $340.12M | $378.78M | $47.22M | $331.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-54.92M ▼ | $-52.3M ▼ | $45.87M ▼ | $13.56M ▲ | $7.13M ▼ | $-52.35M ▼ |
| Q2-2025 | $-49.16M ▲ | $-38.07M ▲ | $73.08M ▼ | $153K ▲ | $35.17M ▼ | $-38.09M ▲ |
| Q1-2025 | $-54.36M ▼ | $-50.05M ▼ | $97.62M ▲ | $59K ▼ | $47.62M ▲ | $-50.13M ▼ |
| Q4-2024 | $-48.59M ▼ | $-36.02M ▼ | $1.01M ▲ | $4.97M ▲ | $-30.04M ▲ | $-36.02M ▼ |
| Q3-2024 | $-34.82M | $-32.02M | $-45.93M | $175K | $-77.76M | $-32.02M |
CEO
Douglas E. Love
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 88
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
FMR LLC
Shares:11.08M
Value:$74.02M
BLACKROCK, INC.
Shares:7.9M
Value:$52.77M
ALERCE INVESTMENT MANAGEMENT, L.P.
Shares:7.41M
Value:$49.47M
Summary
Showing Top 3 of 157